Stay updated with breaking news from Nasdaq Allo. Get real-time updates on events, politics, business, and more. Visit us for reliable news and exclusive interviews.
Allogene Therapeutics, Inc. (NASDAQ:ALLO – Get Rating) has been given a consensus recommendation of “Moderate Buy” by the fifteen ratings firms that are covering the company, Marketbeat reports. One analyst has rated the stock with a sell recommendation, three have issued a hold recommendation and eight have assigned a buy recommendation to the company. The […]
Allogene Therapeutics (NASDAQ:ALLO – Get Rating) issued its earnings results on Wednesday. The company reported ($0.68) earnings per share for the quarter, missing analysts’ consensus estimates of ($0.63) by ($0.05), Briefing.com reports. The business had revenue of $0.05 million during the quarter, compared to analyst estimates of $0.08 million. Allogene Therapeutics had a negative net […]
Allogene Therapeutics (NASDAQ:ALLO – Get Rating) had its price target lowered by investment analysts at Stifel Nicolaus from $8.00 to $7.50 in a research report issued on Thursday, The Fly reports. Stifel Nicolaus’ target price suggests a potential upside of 31.12% from the company’s current price. Other equities research analysts have also issued research reports […]
Former Kite Pharma Executive Responsible for the Development and Commercial Launch of Two of the Most Successful Autologous CAR T Manufacturing Processes...
Allogene Therapeutics (NASDAQ:ALLO – Get Rating) had its price objective lowered by HC Wainwright from $29.00 to $23.00 in a research note published on Tuesday morning, The Fly reports. HC Wainwright currently has a buy rating on the stock. HC Wainwright also issued estimates for Allogene Therapeutics’ Q1 2023 earnings at ($0.61) EPS, Q2 2023 […]